IntegraGen Receives Galien MedStartUp Award for Their Collaboration with The Solution Lab on ICE Genomic Software Interpretat...
October 30 2017 - 3:00AM
Business Wire
Regulatory News:
IntegraGen (Paris:ALINT), a company specializing in the
transformation of data from biological samples into genomic
information and diagnostic tools for oncology, today announced that
it received the 2017 Galien MedStartUp award for "Best
Collaboration for a Breakthrough Therapy or Diagnosis” during the
recent MedStartUp Days conference held in New York City. IntegraGen
was presented the award based on its collaboration with The
Solution Lab, a non-profit organization which provides consulting
services to life sciences companies, to explore market dynamics and
potential strategic approaches to the commercialization of
IntegraGen’s Interpretation of Clinical Exome (ICE) software tool
in the U.S. The ICE software is designed to provide a user-friendly
approach for the analysis of genomic data and the application of
precision medicine approaches to the care of cancer patients.
“We are honored to receive this prestigious award from the
Galien Foundation recognizing our collaboration with The Solution
Lab,” stated Larry Yost, General Manager for IntegraGen, Inc.
“Through this effort we were able to obtain direct market feedback
which enables us to better understand key market dynamics and
commercial considerations as we prepare for the launch of our ICE
software in the U.S.”
“Our collaboration with IntegraGen focused on the assessment of
the need for improved software tools to analyze genomic data from
cancer patients,” said Stefanie Mazlish, CEO of The Solution Lab.
“We were able to leverage our expertise and established approach
for assessing markets and obtaining feedback from key opinion
leaders to develop objective product development recommendations
for IntegraGen’s ICE software, from a decidedly US market
perspective.”
The MedStartUp initiative was established by The Galien
Foundation and Business France to encourage
international partnerships between French and North American
innovators in the Life Sciences Industry.
About The Solution Lab
The Solution Lab is a non-profit 501(c) organization which
provides consulting services to the life sciences industry. The
Solution Lab’s expertise is the ability to gain in-depth market
insight for our clients through market research and competitive
analyses that enable the creation of comprehensive assessments of
market entry opportunities. To accomplish the above, we engage
driven and articulate individuals with advanced scientific degrees
who volunteer their time to gain increased insight on the business
world and their own personal development, while also contributing
their personal expertise on subject matter. The Solution Lab’s
approach enables us to assist our clients in gaining a better
understanding of market dynamics and barriers to entry for their
technologies.
For more information, visit www.thesolutionlab.org
About IntegraGen
IntegraGen is a company specializing in deciphering the human
genome and producing relevant and easily interpretable data for
academic and private laboratories. IntegraGen’s oncology efforts
provide researchers and clinicians with sophisticated tools for
analysis and therapeutic individualization of treatment approaches
allowing them to tailor therapy to the genetic profiles of
patients. As of December 31, 2016, IntegraGen had 38 employees and
had generated revenue of €6.0 million in 2016. Based in Evry
Genopole, IntegraGen also has a U.S. office in Cambridge,
Massachusetts. IntegraGen is listed on Euronext Growth (ISIN:
FR0010908723 - Ticker: ALINT - PEA-SME).
For more information, visit www.integragen.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171030005303/en/
IntegraGenBernard COURTIEUPresident and CEOorLaurence
RIOT LAMOTTE, +33 (0)1 60 91 09 00Chief Financial
Officercontact@integragen.comorThe Solution LabStefanie
MAZLISHCEOinfo@thesolutionlab.orgorNewCapInvestor and Media
RelationsLouis-Victor DELOUVRIER, +33 (0)1 44 71 98
53integragen@newcap.eu
Integragen (EU:ALINT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Integragen (EU:ALINT)
Historical Stock Chart
From Jul 2023 to Jul 2024